Report : Asia Pacific Malaria Treatment Market Forecast to 2030 - Regional Analysis - by Treatment (Generic Drugs, Originators, Vaccines, and Others), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
At 30.1% CAGR, Asia Pacific Malaria Treatment Market is Speculated to be Worth US$ 5,179.15 Million by 2030, says Business Market Insights
According to Business Market Insights' research, the Asia Pacific malaria treatment market was valued at US$ 631.37 million in 2022 and is expected to reach US$ 5,179.15 million by 2030, registering a CAGR of 30.1% from 2022 to 2030. Rising initiatives to raise awareness about malaria and increasing prevalence of malaria are among the critical factors attributed to the Asia Pacific malaria treatment market expansion.
Malaria awareness campaigns help enhance the knowledge of the population regarding the disease, thereby promoting healthcare services through intersectoral collaboration and social support. The WHO coordinates with the Global Malaria Programme (GMP) as part of its global efforts for controlling and eradicating malaria. The WHO also observes World Malaria Day on April 25 of every year to highlight the commitment of the communities dedicated to spreading awareness about malaria and its treatment and uniting for the common objective of eliminating malaria cases.
Governments of several countries are taking various initiatives to create awareness and conduct research for the development of new antimalarial drugs and vaccines. As per the WHO data, total funding for the control and elimination of malaria reached ~US$ 3 billion in 2019; the governments of endemic countries such as South Africa and Asia collectively contributed 31% (~US$ 900 million) of the total fund to create awareness and development of new vaccines for the treatment of the disease. Various private companies are also investing heavily in R&D activities to reduce the incidence of malaria.
Governments of various countries across the globe with a high prevalence of malaria are deploying various strategies to eradicate the diseases by improving access to healthcare services, including treatment options, to the people. A few of the initiatives undertaken are as follows:
- Myanmar has a national malaria control plan that the Global Fund has approved, and by 2030, it is expected to eliminate the disease caused by P. falciparum. The universal healthcare coverage in the country also includes access to malaria diagnosis by means of microscopy or rapid diagnostic tests (RDTs) and artemisinin-based combination therapies (ACTs).
- The government of Thailand has implemented a National Malaria Elimination Strategy (NMES) 2017-2026 that further applies an integrated elimination strategy that aims to eliminate the disease by 2024.
Thus, the abovementioned initiatives to spread awareness about malaria disease reinforce the eradication efforts to bolster the malaria treatment market growth.
On the contrary, availability of counterfeit antimalarial drugs followed by subsequent drug resistance hurdles the growth of Asia Pacific malaria treatment market.
Based on treatment, the Asia Pacific malaria treatment market is categorized into generic drugs, originators, vaccines, and others. The vaccines segment held 96.6% share of Asia Pacific malaria treatment market in 2022, amassing US$ 609.85 million. It is projected to garner US$ 5,051.79 million by 2030 to expand at 30.3% CAGR during 2022-2030.
In terms of route of administration, the Asia Pacific malaria treatment market is bifurcated into oral and parenteral. The oral segment held 69.0% share of Asia Pacific malaria treatment market in 2022, amassing US$ 435.77 million. It is projected to garner US$ 3,524.79 million by 2030 to expand at 29.9% CAGR during 2022-2030.
By distribution channel, the Asia Pacific malaria treatment market is categorized into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held 45.6% share of Asia Pacific malaria treatment market in 2022, amassing US$ 288.15 million. It is projected to garner US$ 2,371.99 million by 2030 to expand at 30.1% CAGR during 2022-2030.
Based on country, the Asia Pacific malaria treatment market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that the Rest of Asia Pacific captured 82.9% share of Asia Pacific malaria treatment market in 2022. It was assessed at US$ 523.09 million in 2022 and is likely to hit US$ 4,299.22 million by 2030, exhibiting a CAGR of 30.1% during 2022-2030.
Key players operating in the Asia Pacific malaria treatment market are Cipla Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, AdvaCare Pharma USA LLC, and Lupin Ltd, among others. - In November 2022, Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria.
- In October 2021, GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com